{
  "docId": "019de071-4e1f-74a8-b040-3577ed32c01f",
  "docSlug": "716a1960d23114ac9a8076dbc94bca80",
  "documentTitle": "Tenaya Therapeutics | IPO Presentation Deck | 36 slides",
  "authorId": "tenaya-therapeutics",
  "authorName": "Tenaya Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 26,
  "pageCount": 36,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes a biological mechanism diagram showing how HDAC6 inhibitors target multiple pathways leading to diastolic dysfunction and HFpEF.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-4e1f-74a8-b040-3577ed32c01f/26",
  "deckHref": "/decks/019de071-4e1f-74a8-b040-3577ed32c01f",
  "deckJsonHref": "/decks/019de071-4e1f-74a8-b040-3577ed32c01f.json",
  "deckAnchorHref": "/decks/019de071-4e1f-74a8-b040-3577ed32c01f#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.52,
        "y": 0.68
      },
      "kind": "diagram",
      "text": "Mechanism of action diagram showing HDAC6 inhibitors impacting multiple pathways (metabolism, fibrosis, hypertrophy, autophagy) to reduce diastolic dysfunction",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbdf5d15-6b72-4adb-8098-2ac12a4a6fcd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.22,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "image",
      "text": "Heart cross-section showing stiffness, fibrosis, and LV wall hypertrophy",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8e618e8-e093-470e-94e1-8342f0ca9428",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.23,
        "x": 0.26,
        "y": 0.42
      },
      "kind": "list",
      "text": "Disease Symptoms and Severity: ~24% of HFpEF population has NYHA Class III or IV disease; Mortality for HFpEF patients who were previously hospitalized as high as 75% over 5-year period",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72341fbf-33bd-45de-b760-996b9861fd55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.23,
        "x": 0.26,
        "y": 0.65
      },
      "kind": "list",
      "text": "Standard of Care: Few effective treatments; no disease modifying therapies that improve clinical outcomes",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82b8a280-6744-4ef4-9bf1-c16367455f85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.23,
        "x": 0.26,
        "y": 0.25
      },
      "kind": "list",
      "text": "Pathophysiology: Poor relaxation and filling of the left ventricle (diastolic dysfunction); High overlap with diabetes and obesity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "edce3eb9-8299-4dd4-841d-38e2fc6fb373",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.52,
        "y": 0.2
      },
      "kind": "table",
      "text": "Tenaya Product Concept: TYA-11631, Target Cell, Modality, Target, MOA, Stage",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0d18fee-c7d1-489d-a1d0-287153a88d45",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "Addressing HFpEF, the Leading Cause of Heart Failure Affecting > 3MM Patients in US Alone",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fab78de-7e9a-4244-853d-5cc3009706ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "HDAC6i Small Molecule Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "760229a2-d215-49d6-a16d-304926fc4702",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "1eb620cb-83c4-408a-b809-39162db06456",
      "evidence": "list/bullet: Disease Symptoms and Severity: ~24% of HFpEF population has NYHA Class III or IV disease; list/bullet: Pathophysiology: Poor relaxation and filling of the left ventricle (diastolic dysfunction)",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "fa5c60e0-586b-44d7-9f1c-571361965757",
      "evidence": "The diagram at the bottom illustrates the causal link between cellular pathways, diastolic dysfunction, and HFpEF.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}